Equities analysts predict that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will report sales of $30.90 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Halozyme Therapeutics’ earnings, with the lowest sales estimate coming in at $30.30 million and the highest estimate coming in at $31.49 million. Halozyme Therapeutics reported sales of $33.75 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 8.4%. The firm is expected to announce its next quarterly earnings results after the market closes on Tuesday, August 7th.
According to Zacks, analysts expect that Halozyme Therapeutics will report full year sales of $124.11 million for the current fiscal year, with estimates ranging from $124.00 million to $124.22 million. For the next financial year, analysts anticipate that the firm will report sales of $182.32 million per share, with estimates ranging from $129.01 million to $276.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Halozyme Therapeutics.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, May 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.03. The firm had revenue of $30.90 million during the quarter, compared to analyst estimates of $31.84 million. Halozyme Therapeutics had a return on equity of 45.31% and a net margin of 21.52%. Halozyme Therapeutics’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.26) earnings per share.
Several analysts recently weighed in on the company. ValuEngine raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c” rating in a report on Tuesday, May 15th. Barclays lowered Halozyme Therapeutics from an “equal weight” rating to an “underweight” rating and set a $19.00 price objective for the company. in a report on Friday, May 11th. BidaskClub downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. Finally, Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Wednesday. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $19.67.
Halozyme Therapeutics traded up $0.36, hitting $17.56, during midday trading on Monday, Marketbeat reports. The stock had a trading volume of 747,700 shares, compared to its average volume of 951,271. The company has a quick ratio of 4.03, a current ratio of 4.06 and a debt-to-equity ratio of 0.39. The firm has a market cap of $2.48 billion, a P/E ratio of 38.22 and a beta of 1.90. Halozyme Therapeutics has a 12 month low of $11.41 and a 12 month high of $21.48.
In other Halozyme Therapeutics news, major shareholder Randal J. Kirk sold 304,321 shares of Halozyme Therapeutics stock in a transaction that occurred on Friday, June 29th. The stock was sold at an average price of $17.04, for a total value of $5,185,629.84. Following the completion of the transaction, the insider now directly owns 3,562,388 shares in the company, valued at $60,703,091.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Randal J. Kirk sold 53,505 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, June 27th. The shares were sold at an average price of $17.34, for a total value of $927,776.70. Following the completion of the transaction, the insider now owns 3,562,388 shares of the company’s stock, valued at $61,771,807.92. The disclosure for this sale can be found here. Insiders own 16.80% of the company’s stock.
Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its position in shares of Halozyme Therapeutics by 1.3% during the first quarter. JPMorgan Chase & Co. now owns 3,125,123 shares of the biopharmaceutical company’s stock worth $61,221,000 after buying an additional 39,316 shares during the period. Artisan Partners Limited Partnership boosted its position in shares of Halozyme Therapeutics by 2.8% during the first quarter. Artisan Partners Limited Partnership now owns 1,697,760 shares of the biopharmaceutical company’s stock worth $33,259,000 after buying an additional 46,907 shares during the period. Northern Trust Corp boosted its position in shares of Halozyme Therapeutics by 0.4% during the first quarter. Northern Trust Corp now owns 1,657,580 shares of the biopharmaceutical company’s stock worth $32,472,000 after buying an additional 6,385 shares during the period. Millennium Management LLC boosted its position in shares of Halozyme Therapeutics by 99.0% during the fourth quarter. Millennium Management LLC now owns 1,475,143 shares of the biopharmaceutical company’s stock worth $29,886,000 after buying an additional 733,706 shares during the period. Finally, Prudential Financial Inc. boosted its position in shares of Halozyme Therapeutics by 53.4% during the first quarter. Prudential Financial Inc. now owns 1,395,190 shares of the biopharmaceutical company’s stock worth $27,332,000 after buying an additional 485,904 shares during the period. Institutional investors own 84.87% of the company’s stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.